Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron beats quarterly results on strong demand for eczema, eye treatments
Drugmaker Regeneron Pharmaceuticals exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs.
Regeneron (REGN) Surpasses Q2 Earnings and Revenue Estimates
Regeneron (REGN) came out with quarterly earnings of $11.56 per share, beating the Zacks Consensus Estimate of $10.57 per share. This compares to earnings of $10.24 per share a year ago.
Regeneron Stock Climbs After Strong Second-Quarter Performance
A strong second-quarter performance lifted the already extended shares of the New York-based drugmaker Regeneron.
Regeneron Pharmaceuticals Inc Investors With Losses Are Urged To Contact The Schall Law Firm As It Initiates An Investigation Into Allegations
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Regeneron Pharmaceuticals Inc Investors With Losses Are Urged To Contact The Schall Law Firm As It Initiates An Investigation Into Allegations
LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Countdown to Regeneron (REGN) Q2 Earnings: Wall Street Forecasts for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
LOS ANGELES, CA / ACCESSWIRE / July 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Regeneron (REGN) Earnings Expected to Grow: Should You Buy?
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Regeneron Pharmaceuticals Inc Investors With Losses Are Encouraged To Contact The Schall Law Firm As They Initiate An Investigation Into Allegations
LOS ANGELES, CA / ACCESSWIRE / July 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
